Jeff Garro
Stock Analyst at Stephens & Co.
(0.89)
# 3,744
Out of 4,846 analysts
49
Total ratings
33.33%
Success rate
-11.84%
Average return
Main Sectors:
Stocks Rated by Jeff Garro
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TBRG TruBridge | Reiterates: Equal-Weight | $28 | $23.72 | +18.04% | 3 | Apr 10, 2025 | |
| VEEV Veeva Systems | Reiterates: Overweight | $280 | $278.63 | +0.49% | 2 | Mar 6, 2025 | |
| HCAT Health Catalyst | Maintains: Equal-Weight | $7 → $5 | $3.79 | +31.93% | 4 | Mar 6, 2025 | |
| CERT Certara | Reiterates: Overweight | $17 | $11.00 | +54.62% | 5 | Feb 27, 2025 | |
| EVH Evolent Health | Maintains: Equal-Weight | $16 → $12 | $7.57 | +58.52% | 5 | Jan 21, 2025 | |
| PRVA Privia Health Group | Reiterates: Overweight | $26 | $22.82 | +13.94% | 3 | Jan 7, 2025 | |
| DH Definitive Healthcare | Initiates: Equal-Weight | $5 | $3.26 | +53.37% | 1 | Dec 20, 2024 | |
| DOCS Doximity | Initiates: Equal-Weight | $55 | $51.50 | +6.80% | 1 | Dec 20, 2024 | |
| OPRX OptimizeRx | Initiates: Equal-Weight | $5.5 | $12.35 | -55.47% | 3 | Dec 20, 2024 | |
| IQV IQVIA Holdings | Initiates: Overweight | $250 | $139.10 | +79.73% | 2 | Dec 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $17 | $17.54 | -3.08% | 1 | Dec 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $39 | $26.37 | +47.90% | 1 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $28 | $24.94 | +12.27% | 8 | May 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $28 | $6.87 | +307.57% | 2 | Jul 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $15 → $20 | $15.52 | +28.87% | 3 | Aug 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $5 → $3.9 | $3.87 | +0.78% | 2 | May 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $4 → $3 | $2.15 | +39.53% | 3 | May 6, 2022 |
TruBridge
Apr 10, 2025
Reiterates: Equal-Weight
Price Target: $28
Current: $23.72
Upside: +18.04%
Veeva Systems
Mar 6, 2025
Reiterates: Overweight
Price Target: $280
Current: $278.63
Upside: +0.49%
Health Catalyst
Mar 6, 2025
Maintains: Equal-Weight
Price Target: $7 → $5
Current: $3.79
Upside: +31.93%
Certara
Feb 27, 2025
Reiterates: Overweight
Price Target: $17
Current: $11.00
Upside: +54.62%
Evolent Health
Jan 21, 2025
Maintains: Equal-Weight
Price Target: $16 → $12
Current: $7.57
Upside: +58.52%
Privia Health Group
Jan 7, 2025
Reiterates: Overweight
Price Target: $26
Current: $22.82
Upside: +13.94%
Definitive Healthcare
Dec 20, 2024
Initiates: Equal-Weight
Price Target: $5
Current: $3.26
Upside: +53.37%
Doximity
Dec 20, 2024
Initiates: Equal-Weight
Price Target: $55
Current: $51.50
Upside: +6.80%
OptimizeRx
Dec 20, 2024
Initiates: Equal-Weight
Price Target: $5.5
Current: $12.35
Upside: -55.47%
IQVIA Holdings
Dec 20, 2024
Initiates: Overweight
Price Target: $250
Current: $139.10
Upside: +79.73%
Dec 9, 2024
Initiates: Buy
Price Target: $17
Current: $17.54
Upside: -3.08%
Nov 15, 2024
Initiates: Overweight
Price Target: $39
Current: $26.37
Upside: +47.90%
May 31, 2024
Reiterates: Overweight
Price Target: $28
Current: $24.94
Upside: +12.27%
Jul 26, 2023
Reiterates: Equal-Weight
Price Target: $28
Current: $6.87
Upside: +307.57%
Aug 5, 2022
Maintains: Overweight
Price Target: $15 → $20
Current: $15.52
Upside: +28.87%
May 11, 2022
Maintains: Underweight
Price Target: $5 → $3.9
Current: $3.87
Upside: +0.78%
May 6, 2022
Maintains: Neutral
Price Target: $4 → $3
Current: $2.15
Upside: +39.53%